Founded in 2015, Zetagen is a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions. Our multi-patented, ZetaMet™ technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone. Zetagen exclusively-licensed the platform technology from the State University of New York in 2016. This novel therapy, a drug-eluting implant technology, has successfully passed its preclinical trials and is being prepared for its first human clinical trial in Q4 2021. In addition to ZetaMet™, the Company’s pipeline includes other oncologic treatments for Skeletal Related Events (SREs), i.e., ZetaMet Flowable™ and ancillary osteologic treatments including, ZetaFuse™, ZetaSet™, ZetaDent™ and ZetaBase™. The Company is supported through Series A funding, private and angel investors, and Phase I and Phase II NIH research grants.
Location: United States, New York, City of Syracuse
Employees: 1-10
Total raised: $19.39M
Founded date: 2015
Funding Rounds 2
| Date | Series | Amount | Investors |
| 14.08.2023 | Series B | $9.79M | - |
| 05.02.2023 | - | $9.6M | - |
Mentions in press and media 3
| Date | Title | Description |
| 14.08.2023 | USA-based Zetagen raises USD 9.79 million in Series B | New York, USA-based, a private, clinical-stage, biopharmaceutical company focused on driving breakthrough innovation in the treatment of metastatic cancers to bone and soft tissue organs as well as osteologic interventions, Zetagen Therapeu... |
| 11.08.2023 | Zetagen Therapeutics Raises USD9.79M in Series B Funding | Zetagen Therapeutics, a Syracuse, NYC-based clinical-stage, biopharmaceutical company, raised USD9.79M in Series B funding. Participating in the financing round were New York Ventures and Consolidated Capital Investments, LLC, and private i... |
| - | ZetaGen Therapeutics | “Zetagen is a private, clinical-stage pharmaceutical company developing innovative cancer treatments alongside osteologic interventions.” |